Physician profile
Ari Lamet
NPI 1871723528
$7,428.44
in general payments reported to CMS, 2019-2025
31 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $374 · 2021: $819 · 2022: $958 · 2023: $731 · 2024: $1,579 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,441 · Education: $47.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,441.26 |
| Education | $47.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.30 | 2020-2025 | |
| Janssen Biotech, INC. | $1,130.70 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $865.09 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $802.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $364.58 | 2023-2025 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $327.46 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $268.30 | 2022-2025 | Ocaliva |
| Gilead Sciences, INC. | $190.94 | 2019-2021 | |
| Redhill Biopharma INC. | $151.20 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $149.75 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $141.88 | 2023-2025 | Ibsrela |
| Celgene Corporation | $136.44 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $135.94 | 2024 | |
| Daiichi Sankyo INC. | $109.93 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $108.22 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $88.89 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $84.86 | 2022 | |
| Boston Scientific Corporation | $78.21 | 2020-2021 | |
| Allergan, INC. | $75.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $57.38 | 2019-2023 | Linzess |
| Apollo Endosurgery US INC | $50.76 | 2019 | |
| Aimmune Therapeutics, INC. | $45.95 | 2024 | |
| Celltrion USA INC. | $43.44 | 2024 | Vegzelma |
| Genzyme Corporation | $42.96 | 2025 | |
| Evoke Pharma, INC. | $36.84 | 2023-2025 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $33.14 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.85 | 2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $27.21 | 2024 | Givlaari |
| Novo Nordisk INC | $21.68 | 2025 | Wegovy |
| Lilly USA, LLC | $16.46 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Lamet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.